MARKET

GMED

GMED

Globus Medical
NYSE

Real-time Quotes | Nasdaq Last Sale

49.21
+0.38
+0.78%
After Hours: 49.21 0 0.00% 16:00 09/25 EDT
OPEN
48.60
PREV CLOSE
48.83
HIGH
49.59
LOW
48.51
VOLUME
441.86K
TURNOVER
--
52 WEEK HIGH
60.15
52 WEEK LOW
33.41
MARKET CAP
4.81B
P/E (TTM)
57.37
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Zacks Analyst Blog Highlights: Teradyne, ABB, Brooks Automation and Globus Medical
The Zacks Analyst Blog Highlights: Teradyne, ABB, Brooks Automation and Globus Medical
Zacks · 09/17 14:34
Hedge Funds Never Been This Bullish On Globus Medical Inc (GMED)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually
Insider Monkey · 09/15 04:35
Globus Medical Getting Closer To Key Technical Measure
Investor's Business Daily · 09/04 17:08
Globus Medical (GMED) Down 2% Since Last Earnings Report: Can It Rebound?
Zacks · 09/04 15:31
Moving Average Crossover Alert: Globus Medical
Globus Medical is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Zacks · 09/04 08:19
Stryker Has Looked A Little Mortal Lately, And The Stock Has Suffered
Stryker has continued to beat expectations, but other med-techs have looked more dynamic, and investor enthusiasm seems to have taken a hit. Stryker's core knee business is still quite strong, and Mako placements remain healthy. A shaky hospital capex environment is creating some complications for Stryker, but I'm more concerned about the ongoing weakness in spine and two straight misses in neuro. Stryker will be fine, but this is a stock to monitor if the shares sell off another 15% or so.
Seekingalpha · 09/01 14:28
NuVasive's Valuation Prices In An Excessively Bearish Outlook
NuVasive benefited from improving elective procedure volumes, and revenue beat expectations, but growth lagged rivals like Globus and Medtronic. Delays due to system refinements and COVID-19 have pushed Pulse commercialization into 2H'21, and first-in-man testing for the new robotics system into 2022. The Pulse delays hurt, but NuVasive does have some attractive near-term product opportunities (including X360 and Modulus) and Pulse should eventually help drive some incremental share. The market is pricing NuVasive for sub-20% EBITDA margins and low single-digit revenue growth; doing even modestly better should be enough to drive attractive returns.
Seekingalpha · 08/27 12:14
Globus Medical Sees Strong Rebound Despite Coronavirus Crisis
Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.
Zacks · 08/20 15:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GMED. Analyze the recent business situations of Globus Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GMED stock price target is 60.85 with a high estimate of 67.00 and a low estimate of 55.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 97.78M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.16%
Healthcare Equipment & Supplies
+2.01%
Key Executives
Chairman/Executive Director
David Paul
President/Chief Executive Officer/Director
David Demski
Chief Financial Officer/Senior Vice President
Keith Pfeil
Executive Vice President/IR Contact Officer
Daniel Scavilla
Senior Vice President/General Counsel/Secretary
Kelly Huller
Independent Director
David Davidar
Independent Director
Robert Douglas
Independent Director
Daniel Lemaitre
Independent Director
Ann Rhoads
Independent Director
James Tobin
Independent Director
Steve Zarrilli
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GMED
Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company's products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. QUARTEX is its Occipito-Cervico-Thoracic (OCT) stabilization system. QUARTEX features a threading locking cap to enable low-torque. The Company's portfolio of approved and pipeline Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Globus Medical Inc stock information, including NYSE:GMED real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMED stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GMED stock methods without spending real money on the virtual paper trading platform.